Monday, 12 February 2018
07:45-08:30		Registration and welcoming
		Intravitreal Injection Course
08:30		Criteria for selection of the treatment and the protocol of treatment (disease, comorbidities, age of the patient, availabilityof the patients, organization of the hospital)
09:15		Prevention of endophthalmitis: selection of the eye, prophylaxis treatment injection and reinjection techniques
10:00		Controls and post-injections treatments
10:30		COFFEE BREAK
11:00		Generic and specific complications per pathology (DME, PDR, RVO, AMD, ROP, Coats, etc.)
12:00		Dealing with post-intravitreal injection endophthalmitis
13:00		LUNCH
		News In AMD Management
14:00		AMD: AMD treatment with intravitreal aflibercept or ranibizumab: treatment protocols, efficacy, safety and patterns of response
15:00		PCV: from diagnosis to treatment
15:45		COFFEE BREAK
16:15-17:00		Myopic CNV treatment: long-term results and case study
		Tuesday, 13 February 2018
08:30-13:00		Industry Satellite Symposia
13:00		LUNCH
		Imaging Course
14:00		DME in imaging and OCT/OCT-A: what is important to know
14:30		OCT classification of drusen and macular atrophy - OCT features in wAMD
15:30		COFFEE BREAK
16:00-17:00		OCT-A features of CNV - OCT and OCT-A integrated images for management of wAMD
		Wednesday, 14 February 2018
		Imaging Course
08:30		Imaging intermediate AMD and subclinical neovascularization
08:50		Different CNV types by OCT-A and evaluation of their activity without use of fluorescein angiography
09:10		“Smart-check” of the imaging to assess the response to AMD treatment
09:30		OCT-A findings of PCV and changes under treatment
09:50		OCT-A findings in CSCR, CNV in CSCR, Mactel I and II
10:10		Clinical value of the imaging assessment of the choroid
10:30		COFFEE BREAK
11:00		Peculiar characteristics of myopic CNV on OCT-A and assessment of response to anti-VEGF treatment
11:20		Managing irvine-gass: OCT assessment of macula prior and after cataract surgery and response to treatment
11:40		Challenges in interpretation of OCT-A images in AMD
		DME In Real Life
12:00		New aspects of biomicroscopic modification of macular stroma and vascularization in the progression of ME
12:30		Correlation of inflammation biomarkers and the stage of ME
13:00		LUNCH
14:00		DME in imaging and OCT/OCT-A: what is important to know
14:30		Intravitreal steroids: biological and clinical differences
15:00		COFFEE BREAK
15:30		Real life data of DME intravitreal treatments and patients management
16:00-16:30		Intravitreal treatment: burden for patients and payers
		Thursday, 15 February 2018
09:00		Use of anti-VEGF as prevention of PDR
10:00		Anti-VEGF safety
10:30		COFFEE BREAK
11:00		Combining or switching treatment for DME
11:45		Use of micropulse laser in DME treatment
12:30		Chronic and refractory DME: definition and treatment options
13:00		LUNCH
		Diabetic Retinopathy And RVO
14:00		Optimized and realistic treatment of DME
14:45		PDR treatment with anti-VEGF: beyond protocol results what is the clinical application?
15:30		COFFEE BREAK
16:00-17:00		Intravitreal steroids and anti-VEGF treatment of ME in RVO: Case study
		Friday, 16 February 2018
		Uveitis Course
08:30		Infectious uveitis manifestations, diagnosis and treatment
09:30		Non-infectious uveitis manifestation and diagnosis and treatment
10:30		COFFEE BREAK
11:00		Deliver of corticosteroids in non-infectious uveitis: systemic, intravitreal, suprachoroidal, subtenonians, subconjunctival
11:30		Case study of infectious uveitis
12:00		Case study of non-infectious uveitis
12:30-13:00		Test, certificates and farewell

Fachärzte/-innen	Gebühren ab gebührenfrei
Ärzte/-innen in Weiterbildung	Gebühren ab gebührenfrei

 

Please contact the organizer for further information.

Zertifizierung beantragt für 23 CME Punkte bei der European Accreditation Council for Continuing Medical Education (EACCME)